In the treatment course of pancreatic ductal adenocarcinoma (PDAC), neoadjuvant therapy (NAT) is emerging within the standard of care to screen resection candidates for aggressive disease, control local and metastatic progression, and potentially downstage borderline disease[1,2]. Imaging assessment of PDAC response to NAT relies on interpretation of changes in vascular involvement, tumor attenuation, and tumor size that are frequently utilized as imaging markers for therapeutic response[3,4]. H…